Navigation Links
Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
Date:5/31/2012

sks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; and increased scrutiny of the health care industry by government agencies. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 1, 2012. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither Janssen Research & Development, LLC nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.)

Media contacts: 
Ernie Knewitz 
Phone: (908) 927-2953 
Mobile: (917) 697-2318 
eknewitz@its.jnj.com

Christina Chan 
Phone: (908) 927-5769
Mobile: (908) 635-2406
cchan20@its.jnj.com

Investor contacts: 
Stan Panasewicz
Phone: (732) 524-2524 

Louise Mehrot
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
2. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
3. AUDIO from Medialink and Ortho-McNeil-Janssen Pharmaceuticals Inc.: Getting Ready for Cold and Flu Season
4. Nominations Open for the 2010 Dr. Paul Janssen Award for Biomedical Research
5. WuXi PharmaTech Enters into Collaboration with J&JPRD, a division of Janssen Pharmaceutica for Preclinical Services and Training
6. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Agrees to $75 Million Settlement for Topamax(R) False Claims Lawsuit
7. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Resolves Investigation of Past TOPAMAX(R) Marketing and Promotional Activities
8. The Pittsburgh Life Sciences Greenhouse Congratulates Diamyd Medical on Its Agreement with Ortho-McNeil-Janssen Pharmaceuticals to Develop Diabetes Therapy
9. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Announces Oncology Research Collaboration Agreement with the Koch Institute for Integrative Cancer Research at MIT
10. Dr. Paul Janssen Award for Biomedical Research Issues Call for Nominations
11. Lilly Makes an Irrevocable Offer to Acquire Janssen Animal Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  eRelevance Corporation ( ... announced today that it has completed integration with ... for Plastic Surgery and Dermatology practices. ... value to healthcare practices using Nextech," stated ... Corporation. "Using information from the EMR we are ...
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Eisai Limited is ... introduction of the first-of-its-kind comic book available in ... has been designed specifically to educate children and their parents ... Canada affecting more than 300,000 Canadians. Eisai is ... care (hhc) , in which the patient is central – ...
(Date:8/21/2014)... 2014 /PRNewswire-iReach/ -- Inc. magazine today ... third straight year, No. 349 in Health on ... of the nation,s fastest-growing private companies. The list ... important segment of the economy—America,s independent entrepreneurs. Companies ... LinkedIn, Zillow, and many other well-known names gained ...
Breaking Medicine Technology:eRelevance Corporation Integrates with Nextech Electronic Medical Records 2Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3
... 11, 2007 - New data,supporting the clinical development ... oral protease inhibitors for the,treatment of hepatitis C ... Annual Meeting of the European Association for the,Study ... In total, nine,abstracts related to telaprevir have been ...
... 11, 2007 /PRNewswire-FirstCall/ -- Vical,Incorporated today announced ... company's Vaxfectin(TM) adjuvant generated up,to 60-fold higher ... same dose in a recently completed study ... vaccine with,Vaxfectin(TM) also allowed a nearly 10-fold ...
Cached Medicine Technology:Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 2Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 3Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 4Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 5Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 6Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine 2Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine 3Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine 4Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine 5
(Date:8/23/2014)... Cardiomyopathy (heart muscle disease) is ... myocardium (the heart muscle) for any reason, usually ... (breathlessness) and peripheral edema (swelling of the legs). ... dangerous forms of irregular heart beat and sudden ... is dilated cardiomyopathy. , Clinical trial report, “Cardiomyopathy ...
(Date:8/23/2014)... 23, 2014 The report “Polycarbonate ... & Forecasts to 2018” defines and segments the ... of the global revenue and consumption. It also ... polycarbonate resin market with analysis of trends, opportunities, ... and consumption and revenues are forecasted on the ...
(Date:8/23/2014)... 2014 According to the new ... Application and Geography - Regional Trends & Forecast ... Market with an analysis and forecast of value ... of electronic adhesives by applications and geography are ... market data tables and 26 figures spread through ...
(Date:8/23/2014)... August 23, 2014 A team of New ... last longer when preceded by surgery and delivered by an ... the new study. Click here to read it now ... the cases of mesothelioma patients who underwent hemithoracic ... radiotherapy dose to the shape of a tumor. Patients ...
(Date:8/23/2014)... August 23, 2014 On Monday, August ... a data breach suffered by Community Health Systems, ... compromise of 4.5 million records containing Personally Identifiable Information ... According to Mandiant, who was engaged to investigate the ... an advanced group of cyber attackers based in China, ...
Breaking Medicine News(10 mins):Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 2Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 3Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 4Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 2Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 3Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 4Health News:Electronic Adhesives Market Poised to Reach $5.5 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Electronic Adhesives Market Poised to Reach $5.5 Billion by 2019 - New Report by MarketsandMarkets 3Health News:New Study Links Hospital Experience and Prior Surgery with Mesothelioma Radiation Success, According to Surviving Mesothelioma 2Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 2Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 3Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 4
... Reports’ has just enabled some valuable advice about chicken, which ... From virus to bacteria//, chicken seems to be hounded incessantly ... of 525 chickens, it found that nearly 83% of the ... or both. The bacteria are known to trigger diarrhea, cramping, ...
... study conducted by Asher Chanan-Khan, MD, Department of Medicine, ... for relapsed chronic lymphocytic leukemia (CLL) or diseases that ... response to the therapy. The results of this study ... Journal of Clinical Oncology. ,"Chronic lymphocytic ...
... a global initiative to develop a vaccine against malaria,// the ... ,The objective for the ‘Malaria Vaccine Technology Roadmap’ is ... fight Malaria by the year 2015. ,Malaria ... and rightly it is one of the oldest diseases in ...
... The popular hair-growth drug finasteride, taken by millions of ... antigen (PSA) test,// the standard screening test for prostate ... involving 308 men ranging in age from 40 to ... medical journal The Lancet and is scheduled to be ...
... was the focus of attention following an E. coli outbreak. ... with abdominal cramps, //fever and diarrhea. They were diagnosed with ... restaurants, operated by Yum Brands Inc in New Jersey have ... of the sick people reported that they had eaten from ...
... under Section 5 of the Insecticides Act, 1968 registers ... safety.// Toxicity and residues data generated under supervised trials ... (MRLs) by the Ministry of Health & Family Welfare ... Rules framed thereunder. The inspection of fruits and vegetables ...
Cached Medicine News:Health News:Hair-Growth Drug Artificially Lowers Psa Levels in Prostate Cancer Screening 2
Angled shaft with 0.2 tip, round serrated handle, dull finish, overall length 130 mm...
... simplus multi-action solution is the first and ... only cleans, disinfects and conditions gas permeable ... with cleaning comparable to the leading two-bottle ... system provides comfort upon insertion by enveloping ...
Menicon Z is a rigid gas lens with high oxygen permeability. As one of its specific characteristics, it can provide superior visual correction and show excellent performance against astigmatism....
... using sophisticated lathing techniques, intrinsically permeable polymers ... a center thickness of just 0.08 across ... powered Thinsite lenses maintain a 30% decrease ... unique design eliminates stress points to reduce ...
Medicine Products: